Oral Low-molecular Weight Hyaluronic Acid in the Treatment of Atrophic Vaginitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02014428|
Recruitment Status : Completed
First Posted : December 18, 2013
Last Update Posted : December 18, 2013
|Condition or disease||Intervention/treatment||Phase|
|Atrophic Vaginitis||Dietary Supplement: Hyaluronic acid Drug: Placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Primary Completion Date :||April 2013|
Experimental: Hyaluronic acid
220 mg hyaluronic acid per tablet (two tablets/day for 10 days, and subsequently one tablet/day for three months)
Dietary Supplement: Hyaluronic acid
Placebo Comparator: Placebo
two tablets/day for 10 days, and subsequently one tablet/day for three months
- Atrophic vaginal changes [ Time Frame: Change from baseline epithelium at 3 months ]Morphometric analysis of biopsies.
- Assessment of Itching [ Time Frame: Change from baseline Itching at 3 months ]Scale: absent, mild, moderate, severe.
- Assessment of Burning [ Time Frame: Change from baseline Burning at 3 months ]Scale: absent, mild, moderate, severe.
- Assessment of Dyspareunia [ Time Frame: Change from baseline Dyspareunia at 3 months ]Scale: absent, mild, moderate, severe.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02014428
|Department of Gynecological, Obstetric Sciences and Reproductive Medicine, University of Messina.|